Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy

April 25, 2016 updated by: Indiana University

Endotracheal Intubation vs. Laryngeal Mask Airway for Esophagogastroduodenoscopy in Children

Esophagogastroduodenoscopy (EGD) is a relatively common procedure in pediatric patients undergoing evaluation for various gastrointestinal ailments. The procedure itself, with or without associated biopsies, is relatively short in length. Unlike adults, who regularly undergo this procedure with conscious sedation, children most often require general anesthesia. While safe and effective, endotracheal tracheal tube (ETT) intubation of children for EGD can result in delayed awakening and slow room turnover, particularly when intravenous medications are required for intubation. Laryngeal mask airway (LMA) is an alternative to intubation, which permits removal before full awakening.

Although considered a safe alternative to tracheal intubation in appropriate cases, disadvantages of the LMA have been reported including kinking, occluding view of the surgical field, failure of placement requiring tracheal intubation, aspiration of gastric contents, desaturation, and laryngospasm. The study was designed to determine whether use of an LMA for EGD could reduce operating room time, while providing satisfactory conditions for the endoscopist, and an equivalent side effect and safety profile as compared to ETT in otherwise healthy children with gastrointestinal complaints

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

  1. Study design The study will be randomized, controlled, and prospective in design.
  2. Comparison groups The two comparison groups will be:

    1. Laryngeal Mask Airway Group (LMA), N = 42 LMA will be used as the intraoperative airway device.
    2. Endotracheal Tube Group (ETT), N = 42 ETT will be used as the intraoperative airway device.
  3. Study and timeline of interventions

    1. Preoperative: All patients enrolled in this study will receive a standard preoperative dose of oral midazolam 0.5 mg/kg up to 15 mg, 15 to 30 minutes prior to anesthetic induction.
    2. Intraoperative: Subjects will all undergo induction of anesthesia by inhalation of sevoflurane and oxygen. An intravenous catheter (IV) will be placed, followed by lidocaine 2mg/kg IV. The airway device will be placed (LMA or ETT). As required for the procedure, the subject will be placed in a left lateral decubitus (left side down) position. Maintenance of anesthesia will be provided with sevoflurane at a concentration of 1.5-2 MAC, or higher if deemed appropriate for the clinical setting as judged by the anesthesiologist. All participants will be given the anti-nausea medicine ondansetron 0.1mg/kg (maximum 4 mg) after placement of the airway device. When the endoscope is removed at the completion of the procedure, the patient will be returned to the supine position. The sevoflurane will be discontinued and the airway device will be removed when the anesthesiologist deems it appropriate. Prior to leaving the OR, the anesthesiologist may give pain or anti-anxiety medicine as needed.
    3. Postoperative: All patients will receive routine PACU care. Pain and anxiety scores will be recorded according to routine PACU practice. Medication for pain, nausea, and anxiety will be given according to the judgment of the anesthesiologist.
    4. Measured end-points:

    i. Time from induction of anesthesia to placement of the airway device ii. Time from end of procedure to arrival in the PACU iii. Time spent in the PACU iv. Overall time from arrival in the OR to discharge home v. Vomiting after the procedure vi. Nausea requiring medicine after the procedure vii. Lowest oxygen saturation level during or after the procedure viii. Highest concentration of sevoflurane during the procedure ix. Highest pain level after the procedure x. Amount of pain medicine given xi. Adverse events xii. Satisfaction level of the doctor doing the EGD

Study Type

Interventional

Enrollment (Actual)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Riley Hospital for Children at IU Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:• Age 3-17

  • Scheduled for Esophagogastroduodenoscopy, with or without biopsies
  • Have been informed of the nature of the study and informed consent has been obtained from the legally responsible
  • Have provided assent in accordance with Institutional Review Board requirements
  • Are able to complete pain assessment evaluations as determined by preoperative evaluations

Exclusion Criteria:

  • • Abnormal/difficult airway

    • Symptomatic obstructive sleep apnea
    • Risk of aspiration of stomach contents
    • Upper respiratory infection within last 14 days
    • Allergy to lidocaine or ondansetron
    • EGD procedures associated with the need to exclude ondansetron administration
    • BMI >85th percentile for age
    • Are unable to communicate effectively with study personnel
    • Have a positive urine pregnancy test (menstruating females only at screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Largyngeal Mask Airway for EGD procedure
Patients randomized to LMA to maintain airway through EGD procedure
Patients randomized to the LMA group had their airways maintained with a LMA device
Active Comparator: Endotracheal Tube for EGD procedure
Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endoscopist Satisfaction
Time Frame: 2 hours

Endoscopist was surveyed to determine their satisfaction with each of the airway devices.

Endoscopist used the following satisfaction scale for each patient, regardless of the airway device used:

  1. The airway device did not interfere at all with the ability to perform the scope.
  2. The airway device presented some interference with the scope, but not enough to cause difficulty.
  3. The airway device made it difficult to perform the endoscopy.
  4. The airway device prevented the endoscopy from being performed.
2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OR to Discharge (Min)
Time Frame: OR to discharge
Overall time from arrival in the OR to discharge home (in minutes)
OR to discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Micahel Acquaviva, MD, Indiana University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

August 29, 2013

First Submitted That Met QC Criteria

September 5, 2013

First Posted (Estimate)

September 6, 2013

Study Record Updates

Last Update Posted (Estimate)

May 2, 2016

Last Update Submitted That Met QC Criteria

April 25, 2016

Last Verified

April 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 1011002885

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Airway Morbidity

Clinical Trials on LMA

Subscribe